Founder, President, CTO
For more than 15 years, Richard Terry has led cross-functional teams in the development of innovative and novel technologies. His unique background in aerospace engineering, physics and biochemistry is a testament to his ability to transcend barriers and bring together a diverse set of resources to achieve the impossible. Richard’s research interests include applying systems-level engineering to biological challenges, and he is a prominent expert in synthetic biology.
Prior to launching ReadCoor, Richard was Lead Senior Staff Scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he supported advancements in reading, writing and editing nucleic acid, better known as nucleic acid sequencing, gene synthesis, and gene editing. Richard was one of the institute’s first hires and joined the founding team before the research center opened its doors. He built and transformed the Synthetic Biology group from its earliest form into the world-renowned Translational Synthetic Biology group that it is today. A sample of the tools developed by the Synthetic Biology group under his charge includes Ultra-Long DNAs, Next Gen Sequencing, Nanopore Sequencing, Multiplexed Automated Genome Engineering (MAGE), Programmable DNA Nanotherapeutic Robotic Device, CRISPR, TALEN, Zinc Finger, CADnano, SeqTag, Data Encoding and Enzymatic Synthesis of DNA.
Before joining the Wyss, Richard resided in the Church Lab at Harvard Medical School. During his time in the lab he designed, developed, and produced a cost-effective, high throughput, open source DNA sequencer: The Polonator. Prior to his time at the Church Lab, Richard developed implantable nerve stimulation devices to treat vestibular disorders at the Massachusetts Eye and Ear Infirmary. He also held the position of Senior Project Manager for an optical subsystem of the Large Hadron Colliders (LHC) at The Center of European Nuclear Research (CERN) in Geneva, Switzerland. While completing his graduate degree and following its completion, he conducted urology research for diagnostic devices at Boston Medical Center. He has served as a consultant for a diverse selection of companies ranging from medical device startups to large manufacturing firms (Johnson & Johnson, NeuroKinetics, Intelligent Bio Systems, Good Start Genetics, ABVitro, Merck, Fero Solutions, Halcyon Molecular, Gen9, and Helicos Biosciences). Additionally, he founded a DNA sequencing chemistry company and an engineering consulting firm. Terry received his Master of Science in Aerospace Engineering from Boston University, and has numerous patents and publications spanning multiple disciplines.
Co-Founder, Chairman, CEO
Shawn Marcell has 25 years of executive experience leading interdisciplinary teams in technology and the life sciences. His background includes venture creation, growth acceleration and raising more than $300M in capital for private and public companies.
Prior to co-founding ReadCoor, Shawn was an Executive in Residence at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he oversaw a talented team of business professionals in the development of the ReadCoor business plan and corporate strategy. The team went on to raise one of the largest series A financings in 2016 and was featured in the journal Nature Biotechnology as top ten startup of the year. Shawn has founded and chaired several early stage venture-backed companies in the life sciences including RedPoint Bio (public in 2005), SeniGen (acquired by Sequenom), Lifecodes (division of Hologic acquired by Immucor), and Metamark Genetics.
In addition to launching multiple startups, Shawn’s leadership experience includes large corporations, academic institutions and venture capital funds. He taught entrepreneurship and venture creation at University of Pennsylvania’s Wharton School, and was President of the Port of Technology in Philadelphia, one of the largest life sciences and technology incubators in the United States. He launched and led the University City Science Center’s inaugural venture fund in Philadelphia, and served as Executive in Residence at Excel Venture Management, a leading Boston life sciences technology venture fund. Currently Shawn is a member of the Monell Chemical Senses Center’s International Advisory Council, and a Fellow and Advisory Board Member of the University of Pennsylvania’s Weiss Tech House.
For more than two decades, Shawn has been actively engaged in philanthropic causes. He was a Founder and Board Member of Gilda’s Club in New York City, a community provider of support services for cancer patients and their families. He served as Chairman of the Board of The Calcutta House in Philadelphia, an organization providing residential care facilities for people living with AIDS. Most recently he established a martial arts program at Nashoba Learning Group in Bedford, Massachusetts for children and adults with autism spectrum disorder. He holds a Bachelor of Arts in Economics from George Washington University.
Co-Founder, SAB Chairman
Founding Core Faculty Member, Synthetic Biology Platform Lead, Wyss Institute for Biologically Inspired Engineering at Harvard University
Professor of Genetics, Harvard Medical School
Professor of Health Sciences and Technology, Harvard and MIT
George Church is a renowned geneticist at the forefront of genomic breakthroughs including next generation, DNA sequencing, and CRISPR. George is co-founder of ReadCoor and Chairman of the Scientific Advisory Board. He and his team initiated FISSEQ (Fluorescent In-Situ Sequencing) in 1999 and developed it at the Wyss Institute for Biologically Inspired Engineering and Harvard Medical School.
George leads the Wyss Synthetic Biology Platform, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bioenergy. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including AbVitro (now Juno), Editas Medicine, Veritas Genetics, Warpdrive Bio, Egenesis (transplantation) and ReadCoor (panomic spatial sequencing).
George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center since 1987 and Director of the National Institutes of Health Center of Excellence in Genomic Science since 2004. He is member of the National Academy of Sciences and Engineering and has received the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, and the 2009 Promega Biotechnology Research Award from the American Society for Microbiology. George received the Scripps Genomic Medicine award in 2016, and the following year was named to TIME’s list of 100 Most Influential People. George received his B.A. in Zoology and Chemistry from Duke University and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.